Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inhibition of EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutation, and Her2 exon 20 YVMA and EGFR WT A431. IC50 were 20.4, 20.4, 1.1, 7.5 and 80.4 nM, respectively.
説明 | Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inhibition of EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutation, and Her2 exon 20 YVMA and EGFR WT A431. IC50 were 20.4, 20.4, 1.1, 7.5 and 80.4 nM, respectively. |
ターゲット&IC50 | EGFR (L858R/T790M):1.1 nM, HER2 exon20 YVMA:7.5 nM, EGFR (exon 20 insertion):20.4 nM |
In vitro |
Sunvozertinib inhibits p-BTK with an IC50 of 1.6 nM.[1] The GI50 of Sunvozertinib against EGFR exon NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 Exon20 YVMA, and EGFR WT was 60.4, 83.2, 3.3, 101.3, and 47.1 nM A431, respectively. The GI50 of Sunvozertinib for BTK WT OCI-LY-10, BTK WT TMD-8, BTK WT Ri-1, and non-BCR activated DB was 3.2, 5.8, 51.3 and 1983.5 nM, respectively.[1] |
別名 | DZD9008, DZD 9008, DZD-9008 |
分子量 | 584.08 |
分子式 | C29H35ClFN7O3 |
CAS No. | 2370013-12-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (94.16 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sunvozertinib 2370013-12-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR BTK DZD9008 DZD 9008 DZD-9008 Inhibitor inhibitor inhibit